Notably, thymic involution has been shown in the past to be associated with increased levels in the thymus of distinct cytokines, among them also interleukin (IL)‐6, which itself represents a promising biomarker for severely ill COVID‐19‐infected patients60, 61 and qualified in the recent past as a potent target for immune intervention in severely ill COVID‐19‐infected patients using Tocilizumab.62 This evidence concerns the gene IL6 and COVID-19.